Purpose Women with breast cancer, who are found to be BRCA1/2 mutation carriers, have a high risk of ovarian cancer and metachronous breast cancer. Treatment-focused genetic testing (TFGT), offered around the time of diagnosis, allows genetic test results to inform surgical treatment decisions. However, concern has been raised that offering TFGT at this time may overly increase psychological burden. This study aimed to qualitatively explore women's attitudes and experiences of TFGT. Methods Women who had been diagnosed with breast cancer at age 50 years or less undertook a semi-structured telephone interview (n026). The sample included women who had been offered TFGT, based on family history and/or other risk criteria (n014), and women who had been diagnosed within the past 6-12 months and had not been offered TFGT (n012). Interviews explored women's attitudes towards TFGT, perceived benefits and disadvantages, implications of TFGT and impact on surgical decision making. Interviews were transcribed verbatim and thematically analysed. Results Women expressed positive attitudes towards TFGT and felt it was highly relevant to their surgical decision making. They did not feel that an offer of TFGT shortly after, or at the time of diagnosis, added undue psychological burden. The majority of women interviewed felt that TFGT should be incorporated into standard clinical care. Conclusions TFGT is viewed favourably by women newly diagnosed with breast cancer. Future randomized controlled trials are needed to examine the long-term impact of TFGT. We conclude that an offer of TFGT is not perceived as 'too much, too soon' by relevant patients.
Introduction
Traditionally genetic testing for genes associated with the hereditary breast/ovarian cancer syndrome has been offered to those with a moderate-to high-risk family history of these cancers. However, from 6% [1] to 78% [2] of germline BRCA1/2 mutation, carriers have no striking family history and several studies have shown that women with early onset breast cancer and only a small number of first-and/or second-degree relatives with breast or ovarian cancer are at higher risk of carrying a BRCA1/2 mutation than the general population [1, 3, 4] and therefore could be suitable for genetic testing.
Treatment-focused genetic testing (TFGT) for germline BRCA1 or BRCA2 gene mutations describes the process of genetic risk assessment and testing initiated at a time point to aid selection of cancer treatment and/or prevention. It has been used to provide women who are recently diagnosed with breast cancer with important information on which to base their treatment decisions [5] [6] [7] . Several factors point to the utility of TFGT at this time. Women that are found to be carriers of a BRCA1/2 mutation have a 43 and 35% risk of contralateral breast cancer with BRCA1 and BRCA2 mutations, respectively [8] and a 42-48% risk of ipsilateral breast cancer recurrence by 13 years [9] . Bilateral prophylactic mastectomy is known to reduce the risk of metachronous breast cancer in BRCA mutation carriers by 96% [10, 11] . Bilateral risk-reducing salpingo-oophorectomy (RRSO) before the age of 50 also reduces the risk of breast cancer in these women by 53% and the risk of ovarian cancer by 90%, which offers a significant advantage given the limitations of surveillance for ovarian cancer and poor prognosis [12, 13] . During preoperative chemotherapy, women who have a known BRCA1/2 mutation can be counselled regarding whether to undertake contralateral prophylactic mastectomy, breast reconstruction and RRSO. Given that radiation therapy can interfere with plastic surgical reconstruction options, decisions regarding prophylactic management are best made when BRCA status is known [6, 14] . In the future, TFGT may also guide adjuvant chemotherapy, if agents that target BRCA mutations, such as poly(ADP-ribose) polymerase inhibitors [15] , progress into the adjuvant setting. The concern, however, is that TFGT may also increase the burden of decision making at a vulnerable time for newly diagnosed women, especially if the genetic test result is inconclusive, or if surgical treatment is delayed whilst waiting for the test result [14] . An inconclusive test result can occur when a deleterious BRCA1 or BRCA2 gene mutation is not detected in a woman with a strong family history of breast and/or ovarian cancer. As not all deleterious mutations have been discovered, it is still possible that the woman carries an unknown mutation and may still be at increased risk.
In the past, BRCA genetic test results have taken several months to be returned to patients. With the improvements in genetic testing technology, it is now possible for test results to be available within 1 to 2 weeks, allowing treatment decisions to be made in a timely manner. Palomares et al. [16] recommended that the optimum time for offering TFGT was during adjuvant chemotherapy, after excision of the primary tumour, to enable final surgical decisions regarding breast conservation or mastectomy to be made before radiotherapy would otherwise commence. They found that it was possible to obtain genetic testing results within this time frame (3-4 weeks) .
It has been shown that newly diagnosed breast cancer patients are willing to undergo TFGT when available [14] and that it can be integrated into clinical practice [14, 17, 18] . Additionally, a high percentage of women opting for genetic testing (48%) elected to have bilateral mastectomy if they were found to carry a BRCA mutation [19] . Whilst the feasibility of TFGT has been demonstrated, less is known about the acceptability and the psychosocial impact of offering this form of testing to women newly diagnosed with breast cancer, particularly amongst those without a strong family history of breast or related cancers. Schlich-Bakker et al. [20, 21] evaluated the impact of actively offering pedigree analysis and subsequent referral for genetic counselling to a group of women recently diagnosed with breast cancer and found that psychological distress did not increase. Looking more specifically at TFGT, a focus group study, assessing the perspectives of 13 mutation carriers from high-risk families, reported that women felt that the offer of genetic testing around the time of a breast cancer diagnosis may be too stressful, with women already having multiple demands on their coping abilities [21] . The focus group, however, did not include women who had actually undergone TFGT and was limited only to women with a strong family history of breast or related cancers. As can be seen, the impact of TFGT is yet to be fully explored. What is known is based on pilot data, or extrapolated from the perspective of other target groups, such as those being offered genetic counselling only, without TFGT, or those considering a hypothetical scenario. Research, to date, has also been limited to those with an existing family history of breast or ovarian cancer.
The aim of this study was to qualitatively explore the actual experience of women who were eligible for and had TFGT during their treatment process, as well as the hypothetical views towards TFGT of women who had been diagnosed with breast cancer, but had not had TFGT. The views of women with and without a strong family history of breast and/or ovarian cancer were included because both groups are likely to be targeted for TFGT in the near future as risk factors, other than family history, are incorporated into genetic testing criteria.
Method

Sample
Women diagnosed with breast cancer at 50 years of age or younger were recruited to the study. This age criterion was selected as younger women may be more likely to use mastectomy as a preventive measure because they have less life-years at risk that would benefit from a mastectomy. Group 1 comprised of women who had been offered TFGT to facilitate surgical decisions. Women in group 1 had been offered TFGT for a range of indications such as being at high risk based on their family history [22] , or had been diagnosed with cancer before the age of 40 and/or had another risk factor, i.e. another affected family member, or Ashkenazi Jewish ancestry. In Australia, the cost of the consultation with a genetics service is covered by a government subsidy through the national health system (called Medicare [23] ), and there is no cost to the patient for genetic testing. Group 2 included women who had been diagnosed with breast cancer within the last 6-12 months, unselected for family history and who had not had TFGT. To avoid undue participant burden, only women who had not relapsed were included in either group. Women were excluded if they were under 18 years of age, had insufficient English proficiency to undertake the interview unaided or if they had a mental or intellectual disability.
At the time of the study, group 1 received genetic counselling through their local familial cancer service, and all were referred for TFGT. Group 1 were seen on an urgent basis and received genetic testing results within ten working days. Group 2 were identified through their oncology clinic and were not referred for genetic counselling or TFGT.
Recruitment
Group 1 was ascertained through two major familial cancer clinics in Sydney and Melbourne, Australia and group 2 through an oncology clinic at a major teaching hospital in Sydney. All potential participants received a letter of invitation from the treating clinician. Ethics approval was obtained from the relevant Human Research Ethics Committees.
Procedure
Prior to participation, women were mailed a consent form and a one-page information sheet regarding TFGT specifically designed for the purpose of this study. Women were asked to return the signed consent form and to read the information sheet prior to the interview. The study coordinator (MG) contacted each woman who provided informed consent to schedule a telephone interview at a time of their convenience.
Semi-structured telephone interviews were conducted by MG using an interview guide, whilst leaving wording and sequencing of discussion topics open, with probes to elicit more information, as appropriate. The interviews explored women's attitudes towards TFGT, the perceived benefits and disadvantages, perceived impacts on both the patient and family and impact on surgical decision making. Interviews also explored attitudes towards the educational materials posted to participants and preferences regarding the timing of the offer of TFGT, the mode and format of information delivery and format of information delivered, which is reported elsewhere [24] . Emergent themes from early interviews were used to guide lines of questioning in subsequent interviews, to ensure that divergent points of view were explored [25] . Sampling was discontinued when data saturation was reached [26] .
Data analysis
The conceptual framework of Miles and Huberman [25] was used to guide the analysis. Initial themes were identified and MG and KW coded two transcripts concurrently, to confirm reliability of the coding scheme and further refine and expand on emergent themes. If discrepancies occurred with respect to specific themes, discussions took place until consensus was achieved. The remaining transcripts were then coded by EZ, using the qualitative data analysis software QSR NVivo 8.0. EZ also cross-tabulated emergent themes by participant characteristics [25] . The use of multiple coders and analysts is a strategy suggested by Miles and Huberman to reduce the potential for researcher bias and to increase the validity of the findings [25] .
Results
A total 56 letters of invitation were mailed out by the treating centres (see Fig. 1 ). Eleven women did not respond. Of the 39 women who responded, two women declined participation, five were ineligible to participate and one woman could not be contacted for interview. The data for two of the 28 women interviewed were excluded because it was established during their interview that they had genetic counselling and testing after their definitive breast cancer treatment. A total of 26 interviews were transcribed and analysed. Participants (N026) included women with breast cancer who had either previously had TFGT (group 1, n0 14) or women, recently diagnosed with breast cancer, who had not had TFGT (group 2, n012) (participation rate across both groups 55%). Table 1 shows women's sociodemographic, medical and family history characteristics. The mean age of participants at interview was 42 years, with a mean age at diagnosis of 41 years. The majority of participants was married or partnered, had post-school qualifications and had a family history of breast and/or ovarian cancer. Fifty-four percent had children. Hereafter, participants will be denoted by their group (1 or 2); C will denote participants with children and NC participants with no children, followed by their identifier.
Acceptability of TFGT
Treatment-focused genetic testing was equally acceptable to women across both groups, with the majority wanting the offer of genetic testing at or soon after their breast cancer diagnosis (n017). Three women felt that the acceptability of TFGT was conditional on it being offered to women most likely to be found to be mutation carriers, or as long as it did not delay surgical options. For women who had been offered TFGT, the majority (n010) reported deciding to undertake genetic testing as soon as it was first offered, with most of these (n07) expressing the feeling that there was no decision to be made. One participant from group 1 expressed the view that she needed time whilst waiting for her test result, to process the implications of TFGT because she felt overwhelmed by her recent cancer diagnosis. Quotes to illustrate the actual and hypothetical acceptability of TFGT are shown in Table 2 .
Is TFGT a special test?
Women were asked to report whether they perceived TFGT to be different from other tests that they were required to undergo at diagnosis and whether they felt it should be incorporated into their standard medical care. Seven participants perceived that TFGT was different to other tests due to its family implications. Nine women, however, felt that TFGT was no different to other tests they were subjected to shortly after their diagnosis. Twelve participants felt that TFGT should be part of the standard treatment process, offered to all women who met the inclusion criteria. An additional four women felt that it could be included in the standard testing regime, conditional on the test and its implications being adequately explained to patients. A recurring theme expressed by participants was 'it's just another test'. Table 3 presents quotes that illustrate participants' views on TFGT as a test.
Advantages of TFGT
The main advantage of TFGT expressed by participants (n0 13) was the opportunity to receive and emotionally deal with all bad news at one time. Not only was it about dealing with emotional responses 'all in one go' but TFGT also provided the opportunity to receive information to help guide decision making about surgical options. TFGT also offered patients a sense of certainty (n06) and potentially opened up a range of treatment options (n010). A significant motivator for TFGT reported by most participants (n019) was to obtain information about family risk and to provide screening and testing choices, particularly to first-degree relatives, with a view to preventing the disease in others.
Disadvantages of TFGT
Increased anxiety, particularly in relation to waiting for the test result, at an otherwise already overwhelming time was reported as a potential disadvantage by ten participants. However, only two of these participants were from the group that had actually had TFGT. The perceived anxiety associated with waiting for the test result was sufficient for one participant to feel she would decline TFGT, had it been offered to her. Only one participant reported the impact of genetic testing on life insurance as a potential disadvantage of TFGT. Whilst women acknowledged that the offer of TFGT occurs at a highly stressful time, the overriding theme was that the potential benefits of TFGT outweigh the disadvantages.
Four women reported that any cost associated with TFGT would have excluded them from testing, as they would not have been able to afford the additional expense. Almost half of the women interviewed (n011), however, reported that the benefits of TFGT were sufficient to warrant them paying the full cost of testing themselves (estimated to be over AUD2000), and an additional nine participants felt they would pay part of the cost. Table 4 presents quotations illustrating participants' views regarding the advantages and disadvantages of TFGT.
Implications of TFGT
Implications for the patient A number of women (n08) felt the focus of testing shortly after diagnosis was to provide information for themselves, contralateral breast cancer, the majority of women (n012) felt they would opt for a bilateral mastectomy. Nine participants expressed concern regarding the increased risk of ovarian cancer, and four would have a bilateral RRSO if they were found to be carriers. The majority of women in group 1 described the genetic test result as a significant element in their decision-making process regarding surgical options (n011). Two women, who were at moderate risk based on family history, who were found not to have a BRCA1/2 mutation, elected a breast conservation approach. Two women found to carry a BRCA1 mutation elected a bilateral mastectomy, with one also choosing RRSO. Women who were at high risk, based on family history, who were found not to carry a BRCA1 or BRCA2 mutation were given an 'inconclusive' result (n010). Of these women, the majority (n06) reported finding this result reassuring and elected conservative treatment. The remaining four women, however, chose to have bilateral mastectomy as they felt their high-risk status was sufficient to warrant preventative measures.
Implications for family members
Fifteen women reported that after their surgical decisionmaking needs had been met, a secondary implication of TFGT was for other family members, particularly for first-degree relatives such as children and siblings. Table 5 presents quotations summarizing participants' views on the actual and hypothetical implications of TFGT for patients and family members.
Communication with family members about TFGT
Whilst the majority (n013) of women reported feeling able to discuss TFGT with their family and the expected implications, several felt that other family issues and the potential for family members to blame themselves in relation to hereditary factors would make the discussion difficult initially. When relationships with specific family members were difficult, several enlisted the assistance of another family member, such as their mother, to contact those relatives. Many women (n011) felt a duty to inform other family members about their decision to have TFGT and the potential implications of a mutation positive result. Table 6 presents quotations illustrating participants' views on communicating with family members about TFGT.
Discussion
TFGT was found to be highly acceptable to women in this study, both amongst those who had and those who had not Absolutely. Yeah, I think it would benefit a lot of women and to be part of the whole-what do you call it, screening-I don't know, screening-to be part of the whole-yeah, it's absolutely necessary. I'm sure there's a lot of people in my situation it has to be.
(1,C,061) Knowing that it's just part of the whole process. That it's just-yeah, you are waiting on all the other tests results anyway, you're waiting on that one too, you're not then sitting down and discussing all the possible implications of the genetics test, and the implications to the family before you even know (1,NC,045) TFGT as part of standard treatment process, with some conditions I think so. If the people have got you know a strong family history I think that maybe it would be good, yeah. (2,C,065) Spelt out, yeah, that's right. You've always got to I guess take the care that just because it's part of the process doesn't mean that these bits are bleeped over and taken for granted sort of thing which is always a risk. (2,NC,073) cover and it has cost me so far $20,000 about. And I'm about to go and have the other breast off and on and the gap on that's going to be about another $6000, $7000 and you know it is terribly expensive you know never mind the loss of earnings, it is an incredibly expensive business having breast cancer, you know a really expensive. And that's not counting the taxis home from chemo and you know etc. etc. (1,NC,052) Table 5 Participants' actual and hypothetical views on the implications of TFGT for oneself and family members
Concept Quotation
Implications for the patient Focus on oneself
You are there primarily for yourself in the first instance, and making decisions that affect you and saving your life, and whatever you find out for your family, for me, is more about forewarning them to be more diligent, but it's not my primary reason for doing it.
(1,C,053) I would say just for myself at the initial because it's going to be, that's the first, you're only thinking about yourself. I mean maybe if you were to speak to a mother, a person who's got a young daughter or something, her answer would be completely different. But I would say myself for now and obviously then you know you will get the results and then you can start asking the questions and what you need to do with the, in regards to your family members. (2,NC,021) Impact on surgical decisions of a mutation positive result I mean obviously down the line we knew because my process took a while and um because I know when I made the decision after seeing Dr [name deleted], that um that I was a carrier because we knew to take off the second breast, so that's what, and it was just crystal clear for me as to what had to be done. (1,C,017) Right, well I would then say "Let's talk seriously about getting rid of the other breast definitely, absolutely, positively", and there are a few minor advantages to that cosmetically in that I haven't yet had my reconstruction, where I'm to be reconstructing two breasts, like now I'd be reconstructing one and perhaps having the mastectomy on the other at the same time, that would be a very satisfying solution to that. (2,NC,034)
Implications for family members
Impact on family members of a mutation positive result But it would mean that I would have to consider having a double mastectomy, and it would be something that my daughter, and my nieces, and my sister would all have to know about it. Yes, they would have to find-I mean, I know my sister doesn't know all that much about the genetic side of things. You know, it's important to know-it's really important to know. (2,C,068) And it was also going to mean that I was going to be bringing bad news to my family because I was going to be telling them that I had this mutation, and my sister, you know, might have to be thinking about that too, although she's 10 years older than me but-I sent her off to go and get her mammogram and ultrasound as soon as I was diagnosed anyway but (1,C,072) experienced it. Participants felt that it allowed them to make informed decisions regarding their treatment options, particularly in light of the increased risk of ovarian cancer and contralateral breast cancer. The majority of participants expressed relief or anticipated relief at receiving an inconclusive result, for the reassurance it gave them regarding their children's subsequent risk. On the other hand, if they were found to be mutation carriers, it was believed to offer the opportunity for genetic testing of unaffected relatives and targeted preventative measures. The immediate clinical utility of this information has been noted in previous research. Schwartz et al. [19] reported 48% of newly diagnosed breast cancer patients with a BRCA 1/2 mutation opting for prophylactic mastectomy. Weitzel et al. [17] found that of 37 women with a recent diagnosis of breast cancer at the time of receiving genetic counselling, 32 proceeded to genetic testing, and of those who received a positive BRCA1/2 test result, 100% chose bilateral mastectomy. Women have also reported finding TFGT and genetic counselling extremely helpful when facing future medical decisions [27, 28] . One of the concerns, however, regarding TFGT has been the potential for an increased psychological burden for women recently diagnosed with breast cancer. A previous study [28] found that breast cancer patients who had been diagnosed within the year prior to genetic testing reported higher breast cancer-specific distress than those who had been diagnosed more than a year prior to testing. Ardern-Jones et al. [29] conducted focus groups with women who had been diagnosed with breast cancer before the age of 40, asking them to consider their response to an offer of TFGT, had it been available to them. They reported a range of attitudes, with the majority feeling that TFGT was 'too much, too soon'. The authors acknowledged, though, that the study was retrospective and asked hypothetical questions about reactions to a future scenario. Vadaparampil et al. [30] , in a qualitative assessment of the impact of a surgeon referral letter on recently diagnosed breast cancer patients' uptake of BRCA genetic counselling, reported that of the women interviewed, few mentioned any implications of genetic counselling on their ability to cope with their recent cancer diagnosis. They did, however, find that women that did not attend genetic counselling reported the offer of genetic counselling and testing shortly after their diagnosis to be overwhelming.
Health professionals have also expressed reservations about offering TFGT to breast cancer patients which could be a barrier to any future, wider, introduction of TFGT [29, 31] . Specifically in a study by Lobb et al. [31] , 34 cancer genetics practitioners considered that TFGT raised a number of ethical issues concerning decision making and consent for women at a time of emotional vulnerability immediately following their breast cancer diagnosis. They also identified the need for practitioners to be aware of the unaffected family members' interest in genetic information and the management of this service within familial cancer clinics. (1,C,047) I was a little bit nervous about how my mother would react. I thought my mother might be thinking it was her fault, but other than that, it was not particularly difficult. I mean, I approached it as its relevance to me and my treatment. I tried, when I discussed it with them first off, almost to shy away, or not make a big deal of it being inherited. Even though I mentioned it, I probably mentioned it being a mutation in my personal make-up rather than inherited. I let that come into the conversation at a subsequent time.
(1,C,072) Duty to inform More of a duty to warn because I didn't want to make a moral judgement that they should, so I didn't say you should go and get tested, I said I have got tested, we, I don't have, I don't have any markers, however I have you know spent two separate hours with the director of the family cancer unit, who's an oncologist and a geneticist and her view is that we have you know a definite predisposition and a significant family history. So you know I'm taking action on that and, and she has said that if you want to do testing or stuff, she's happy to send the information over to you know your GP or something. So I, it was more of a duty to warn in that sense (1,NC,052) I'm surprised because usually the way it seems to work is that you know a new development or a new diagnostic tool happens and it gets introduced and then it just becomes the correct part of management. Participants in our study, however, indicated that they believed they would be able to weigh up and integrate the implications of genetic testing, without causing undue psychological distress. One explanation for the discrepancy between our findings and some of the previous research may be that the context of TFGT is significantly different from that of conventional genetic testing, that is, genetic testing once cancer treatment is complete. TFGT offers significant and personally relevant information on which to base immediate treatment decisions. Participants in this study agreed that a major focus on the relevance of the genetic information for other family members would be better left until after their own cancer treatment was complete and that the focus of TFGT should be on their own surgical decisions. In accord with the views expressed by women in our study, Schlich-Bakker et al. [32] found in a prospective study of 58 women who underwent TFGT that there was no increase in psychological distress 12 months following testing, compared to a control group. Tercyak et al. [33] also reported that the genetic test result did not predict quality of life or distress in women who underwent genetic testing before definitive surgery.
Acceptance of TFGT and the positive attitudes towards it did, however, come with a proviso. Participants in our study expressed the view that whilst they felt TFGT should become part of standard care; they acknowledged that it did have extended impacts on other family members. They recommended it be offered to all women that meet predetermined selection criteria, but felt it required adequate decision-related support.
Women in our study also recommended TFGT be offered before surgical decisions needed to be made. The advantage of offering testing shortly after diagnosis was that it allowed complex decisions about surgical procedures to be addressed at a time when most relevant, so that treatment could be streamlined and targeted. Silva et al. recommended TFGT be offered whilst patients are having neoadjuvant or adjuvant chemotherapy, prior to radiotherapy [6] . Additionally several studies have now shown that TFGT can be incorporated successfully into clinical practice [14, 17, 18] with TFGT being offered before definitive surgical treatment [19, 30] , during systemic therapy [18] , immediately following biopsy or during chemotherapy [17] .
It is important to acknowledge several limitations of this research. The study was retrospective in that some women were asked to reflect on their past experience of TFGT. Furthermore, others who had not had had TFGT were asked about their hypothetical views. A strength of the study is that it provides the first qualitative exploration of women's actual experiences of TFGT, whether from low-, moderate-, or high-risk families. As such, it offers in-depth information on the experiences and acceptability of TFGT amongst breast cancer patients who are likely to be targeted for this type of testing in the near future. Participants expressed the view that the advantages of TFGT outweighed the disadvantages; that with adequate education and support, TFGT could be incorporated into standardized care for young women recently diagnosed with breast cancer and that is was not 'too much too soon'.
